Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2022 - 2025)

Zentalis Pharmaceuticals has reported Other Non-Current Liabilities over the past 4 years, most recently at $500000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $500000.0 for Q4 2025, down 41.11% from a year ago — trailing twelve months through Dec 2025 was $500000.0 (down 41.11% YoY), and the annual figure for FY2025 was $500000.0, down 41.11%.
  • Other Non-Current Liabilities for Q4 2025 was $500000.0 at Zentalis Pharmaceuticals, roughly flat from $500000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ZNTL hit a ceiling of $45.0 million in Q1 2022 and a floor of $500000.0 in Q2 2023.
  • Median Other Non-Current Liabilities over the past 4 years was $1.0 million (2024), compared with a mean of $4.3 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 96.02% in 2023 and later soared 117.8% in 2024.
  • Zentalis Pharmaceuticals' Other Non-Current Liabilities stood at $2.6 million in 2022, then tumbled by 32.06% to $1.8 million in 2023, then crashed by 52.3% to $849000.0 in 2024, then crashed by 41.11% to $500000.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $500000.0 (Q4 2025), $500000.0 (Q3 2025), and $500000.0 (Q2 2025) per Business Quant data.